We have previously shown targeting CD70 in renal cell carcinomas (clear cell and papillary types) and in haematologic malignancies (HL, MM) using anti-CD70-drug conjugates (Law et al, 2006; Oflazoglu et al, 2008; Alley et al, 2009). This evidence concerns the gene CD70 and Hodgkins lymphoma.